S&P 500   3,375.47 (-0.14%)
DOW   27,897.91 (-0.28%)
QQQ   272.26 (+0.15%)
AAPL   458.63 (+1.46%)
MSFT   208.76 (-0.21%)
FB   260.43 (+0.21%)
GOOGL   1,516.87 (+0.64%)
AMZN   3,175.00 (+0.40%)
NVDA   456.88 (-0.16%)
CGC   17.28 (+0.17%)
BABA   253.71 (-0.58%)
TSLA   1,613.91 (+3.80%)
GE   6.61 (-1.64%)
MU   46.10 (-4.91%)
AMD   82.01 (-0.73%)
T   29.89 (-0.96%)
F   7.03 (-1.13%)
ACB   10.27 (+4.80%)
GILD   68.19 (-0.94%)
NFLX   481.93 (+1.36%)
DIS   131.13 (-0.50%)
BAC   26.26 (-1.76%)
BA   175.12 (-0.18%)
S&P 500   3,375.47 (-0.14%)
DOW   27,897.91 (-0.28%)
QQQ   272.26 (+0.15%)
AAPL   458.63 (+1.46%)
MSFT   208.76 (-0.21%)
FB   260.43 (+0.21%)
GOOGL   1,516.87 (+0.64%)
AMZN   3,175.00 (+0.40%)
NVDA   456.88 (-0.16%)
CGC   17.28 (+0.17%)
BABA   253.71 (-0.58%)
TSLA   1,613.91 (+3.80%)
GE   6.61 (-1.64%)
MU   46.10 (-4.91%)
AMD   82.01 (-0.73%)
T   29.89 (-0.96%)
F   7.03 (-1.13%)
ACB   10.27 (+4.80%)
GILD   68.19 (-0.94%)
NFLX   481.93 (+1.36%)
DIS   131.13 (-0.50%)
BAC   26.26 (-1.76%)
BA   175.12 (-0.18%)
S&P 500   3,375.47 (-0.14%)
DOW   27,897.91 (-0.28%)
QQQ   272.26 (+0.15%)
AAPL   458.63 (+1.46%)
MSFT   208.76 (-0.21%)
FB   260.43 (+0.21%)
GOOGL   1,516.87 (+0.64%)
AMZN   3,175.00 (+0.40%)
NVDA   456.88 (-0.16%)
CGC   17.28 (+0.17%)
BABA   253.71 (-0.58%)
TSLA   1,613.91 (+3.80%)
GE   6.61 (-1.64%)
MU   46.10 (-4.91%)
AMD   82.01 (-0.73%)
T   29.89 (-0.96%)
F   7.03 (-1.13%)
ACB   10.27 (+4.80%)
GILD   68.19 (-0.94%)
NFLX   481.93 (+1.36%)
DIS   131.13 (-0.50%)
BAC   26.26 (-1.76%)
BA   175.12 (-0.18%)
S&P 500   3,375.47 (-0.14%)
DOW   27,897.91 (-0.28%)
QQQ   272.26 (+0.15%)
AAPL   458.63 (+1.46%)
MSFT   208.76 (-0.21%)
FB   260.43 (+0.21%)
GOOGL   1,516.87 (+0.64%)
AMZN   3,175.00 (+0.40%)
NVDA   456.88 (-0.16%)
CGC   17.28 (+0.17%)
BABA   253.71 (-0.58%)
TSLA   1,613.91 (+3.80%)
GE   6.61 (-1.64%)
MU   46.10 (-4.91%)
AMD   82.01 (-0.73%)
T   29.89 (-0.96%)
F   7.03 (-1.13%)
ACB   10.27 (+4.80%)
GILD   68.19 (-0.94%)
NFLX   481.93 (+1.36%)
DIS   131.13 (-0.50%)
BAC   26.26 (-1.76%)
BA   175.12 (-0.18%)
Log in

NASDAQ:INNTInnovate Biopharmaceuticals Stock Price, Forecast & News

$0.48
-0.02 (-3.96 %)
(As of 08/13/2020 02:55 PM ET)
Add
Compare
Today's Range
$0.47
Now: $0.48
$0.51
50-Day Range
$0.48
MA: $0.54
$0.64
52-Week Range
$0.37
Now: $0.48
$1.67
Volume717,135 shs
Average Volume525,982 shs
Market Capitalization$20.04 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.39
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Read More
Innovate Biopharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INNT
CUSIPN/A
Phone919-275-1933

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.27) per share

Profitability

Net Income$-27,050,000.00

Miscellaneous

Employees8
Market Cap$20.04 million
Next Earnings DateN/A
OptionableOptionable
$0.48
-0.02 (-3.96 %)
(As of 08/13/2020 02:55 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

How has Innovate Biopharmaceuticals' stock been impacted by Coronavirus?

Innovate Biopharmaceuticals' stock was trading at $0.4715 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INNT shares have increased by 2.8% and is now trading at $0.4849.
View which stocks have been most impacted by COVID-19
.

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) issued its earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.11).
View Innovate Biopharmaceuticals' earnings history
.

Has Innovate Biopharmaceuticals been receiving favorable news coverage?

Media headlines about INNT stock have been trending extremely negative on Thursday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innovate Biopharmaceuticals earned a news impact score of -4.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Innovate Biopharmaceuticals
.

Are investors shorting Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 2,170,000 shares, an increase of 17.3% from the January 31st total of 1,850,000 shares. Based on an average daily volume of 715,800 shares, the days-to-cover ratio is presently 3.0 days. Currently, 8.2% of the company's stock are sold short.
View Innovate Biopharmaceuticals' Short Interest
.

Who are some of Innovate Biopharmaceuticals' key competitors?

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Canopy Growth (CGC), Iterum Therapeutics (ITRM), Neurotrope (NTRP), SCYNEXIS (SCYX) and Aurora Cannabis (ACB).

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the following people:
  • Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
  • Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
  • Dr. Christopher P. Prior, Consultant (Age 66)
  • Jerry Gardner M.D., Head of Clinical Strategy
  • Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

How do I buy shares of Innovate Biopharmaceuticals?

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $0.48.

How big of a company is Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals has a market capitalization of $20.04 million. Innovate Biopharmaceuticals employs 8 workers across the globe.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is www.innovatebiopharma.com.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.